MK-677 (Ibutamoren) Peptide

A 2008 randomized controlled trial (Nass et al., Ann Intern Med) in healthy older adults found that MK-677 administration for 12 months increased GH and IGF-1 to young-adult levels, increased fat-free mass by 1.1 kg, and improved physical function measures without significant adverse effects.

A 1998 study (Murphy et al.) demonstrated that MK-677 reversed diet-induced protein catabolism, increasing nitrogen balance and lean body mass in calorie-restricted subjects within 7 days of administration.

Background: Growth hormone (GH) secretion is tightly coupled to slow-wave sleep (SWS) in healthy young adults, with the largest GH pulse of the 24-hour cycle occurring shortly after sleep onset. Aging is associated with parallel declines in SWS, GH amplitude, and IGF-1, raising the question of whether pharmacological reactivation of the ghrelin/GHSR1a axis can restore the youthful relationship between sleep architecture and somatotropic output. MK-677, an orally active GHSR1a agonist, offered an ideal probe because its 4-6 hour plasma half-life and once-daily oral dosing permit chronic study without disturbing nocturnal sleep with injections.

Study design (Copinschi et al., 1997): In a randomized, double-blind, placebo-controlled crossover trial, healthy young adults received oral MK-677 (25 mg) or placebo at bedtime for seven consecutive nights. Polysomnographic recordings (EEG, EOG, EMG) were performed on the final night, and overnight blood sampling at 15-minute intervals was used to characterize GH, cortisol, prolactin, and ACTH profiles. Sleep stages were scored according to standardized Rechtschaffen and Kales criteria by investigators blinded to treatment assignment.

Key findings:

• REM sleep: Total REM sleep duration increased by approximately 20%, and the duration of individual REM episodes also lengthened, with no shift in REM latency.
• Stage IV (deep slow-wave) sleep: Stage IV duration increased by approximately 50% compared with placebo, with corresponding increases in delta-wave EEG power. This effect is notable because Stage IV sleep is the component most reduced by aging.
• Nocturnal GH: The overnight integrated GH concentration and the amplitude of the major sleep-onset GH pulse were significantly elevated, while pulse frequency was essentially unchanged, consistent with amplification of, rather than disruption of, the endogenous pulsatile pattern.
• HPA axis: Cortisol profiles were minimally affected at the 25 mg dose, although a small early-morning rise in cortisol was observed, consistent with weak cross-activation of corticotroph pathways previously reported for ghrelin and GHRP-6.
• Prolactin: A modest increase was observed, again congruent with known GHSR1a downstream signaling.

Mechanistic interpretation: The investigators proposed that GHSR1a activation in the arcuate nucleus and hypothalamic sleep-regulatory centers enhances GHRH tone while suppressing somatostatin, producing both larger sleep-associated GH pulses and a deepening of slow-wave activity. Because intracerebroventricular ghrelin produces similar effects in rodents, the data support a physiologic role for ghrelin/GHSR1a signaling at the interface of metabolism and sleep regulation.

Subsequent research: Follow-up work in older adults (Copinschi et al., 1998, and later Nass et al., 2008) confirmed that MK-677 can partially restore the youthful GH/IGF-1 amplitude pattern over 1-12 months of dosing, though the magnitude of the sleep architectural effect tends to attenuate over time, suggesting partial receptor desensitization or compensatory hypothalamic adaptation. Independent replication using actigraphy and quantitative EEG has supported the original polysomnographic observations of enhanced SWS, particularly during the first half of the night when GHSR1a tone is naturally highest.

Research relevance: These findings establish MK-677 as a valuable tool compound for investigating the bidirectional coupling between sleep architecture and the somatotropic axis, and for probing whether ghrelin-system agonism can serve as a model for age-related changes in sleep-endocrine integration in preclinical settings.

Long-term MK-677 studies examined effects on bone mineral density. A 2-year randomized trial in elderly adults (Murphy et al., 2001) demonstrated that MK-677 increased markers of bone formation (osteocalcin) within 6 weeks and maintained elevated GH/IGF-1 for the full 2-year period. While BMD changes were modest at 12 months, analysis suggested the bone remodeling cycle requires 18-24 months for detectable density improvements.

Murphy et al. (1998) demonstrated MK-677 reverses diet-induced catabolism within 7 days. In calorie-restricted volunteers (18 kcal/kg/day for 14 days), MK-677 administration restored nitrogen balance to positive values, indicating preservation of lean body mass despite caloric deficit. This anti-catabolic effect was dose-dependent and correlated with GH pulse amplitude increases.

One of the most cited investigations of MK-677 (ibutamoren) is the two-year, randomized, double-blind, placebo-controlled trial by Nass and colleagues (2008), which examined the effects of daily oral MK-677 administration on the somatotropic axis and body composition in healthy older adults. This study remains a landmark reference because it directly addressed whether sustained ghrelin receptor agonism could restore growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in older subjects toward values typical of younger adults.

Study Design

• Subjects: 65 healthy men and women, aged 60-81 years
• Duration: 2 years (104 weeks)
• Intervention: Oral MK-677 25 mg once daily vs. placebo
• Endpoints: Serum GH, IGF-1, lean body mass, fat mass, muscle strength, functional performance

Key Results

• Mean GH levels rose to values comparable to those of healthy young adults, and the increase was sustained throughout the 2-year administration period
• IGF-1 increased by ~88% compared with placebo, with levels returning to a young-adult range
• Fat-free mass increased by ~1.1 kg in the MK-677 group versus placebo
• Total fat mass did not decrease significantly, but body weight increased modestly in the active group
• Fasting glucose rose slightly and insulin sensitivity decreased, consistent with known GH/IGF-1 axis effects
• No measurable improvement in functional strength outcomes was observed in this older cohort

Research Significance

This trial established that long-term oral ghrelin receptor agonism with MK-677 produces durable, physiologically meaningful elevation of the GH/IGF-1 axis without the tachyphylaxis typically observed with injectable GH-releasing peptides. The preservation of pulsatile GH secretion across two years of dosing was a particularly notable finding, distinguishing MK-677 mechanistically from exogenous recombinant GH administration. The metabolic shifts toward reduced insulin sensitivity have since become a central consideration in subsequent research designs.

Earlier work by Chapman and colleagues (1996) had already demonstrated that MK-677 could reverse the relative GH deficiency of aging over shorter periods, restoring 24-hour integrated GH concentrations and IGF-1 levels in older subjects after just a few weeks of dosing. The Nass two-year study extended these observations into the long-term setting, providing the framework that nearly all subsequent ghrelin receptor agonist research has built upon.

Adunsky and colleagues (2011) conducted a multicenter, randomized, double-blind, placebo-controlled trial investigating whether MK-677 (ibutamoren) could accelerate functional recovery following hip fracture in older adults. Hip fracture recovery represents a particularly demanding physiological challenge because catabolic stress, low IGF-1, sarcopenia, and impaired wound healing converge in a single clinical population. This made MK-677 a mechanistically rational candidate, given its capacity to elevate the GH/IGF-1 axis without parenteral administration.

Study Design

• Subjects: 123 older adults (median age ~78 years) recovering from surgical repair of hip fracture
• Intervention: Oral MK-677 25 mg daily versus placebo
• Duration: 24 weeks of dosing with follow-up assessments
• Primary endpoint: Change in gait speed and functional mobility (Modified Physical Performance Test)
• Secondary endpoints: IGF-1, lean mass, adverse events

Key Results

• MK-677 produced sustained elevation of serum IGF-1 across the dosing period, confirming on-target ghrelin receptor activation in this frail population
• A modest improvement in gait speed was observed in the active group at certain interim timepoints
• Composite functional performance trends favored MK-677, though the primary endpoint did not reach predefined statistical significance across all measures
• Lean mass markers showed favorable changes consistent with anabolic activation
• The compound was generally well-tolerated in this older cohort, with adverse events broadly similar to placebo aside from expected metabolic shifts

Research Significance

The hip fracture trial extended the relevance of MK-677 research from healthy aging populations into clinically frail subjects. It demonstrated that oral ghrelin receptor agonism remains pharmacologically active in catabolic states and that IGF-1 elevation is achievable even when baseline somatotropic axis activity is suppressed by acute injury and surgery. The mixed functional findings highlight a recurring theme in MK-677 research: robust biochemical elevation of GH and IGF-1 does not always translate into proportionate gains in performance measures, particularly in subjects with multiple comorbidities. This has informed subsequent research designs that pair MK-677 administration with structured loading or rehabilitation protocols, and that include direct measures of muscle protein synthesis rather than relying solely on functional endpoints.

Murphy and colleagues (1998) published a foundational short-term study that examined whether MK-677 could counteract diet-induced protein catabolism in healthy adults. This investigation is frequently cited as mechanistic evidence that oral ghrelin receptor agonism produces anabolic shifts in protein metabolism that are functionally relevant in catabolic states, not merely changes in circulating hormone concentrations.

Study Design

• Subjects: 8 healthy adult volunteers
• Design: Randomized, double-blind, placebo-controlled, crossover
• Intervention: Oral MK-677 25 mg daily during a hypocaloric, protein-restricted dietary phase designed to induce negative nitrogen balance
• Endpoints: Whole-body nitrogen balance, GH, IGF-1, IGFBP-3, basal metabolic rate

Key Results

• MK-677 administration reversed diet-induced negative nitrogen balance, producing measurable nitrogen retention compared with placebo
• Mean 24-hour GH concentrations and IGF-1 rose significantly during MK-677 dosing, with preserved pulsatility
• IGFBP-3 increased in parallel with IGF-1, consistent with sustained hepatic IGF-1 production
• Basal metabolic rate trended upward in the active group
• No clinically significant adverse events were reported during the short-term dosing window

Research Significance

This study provided early proof-of-concept that MK-677 acts not only as a GH-IGF-1 elevator but as a functional anti-catabolic agent in conditions of caloric and protein restriction. Nitrogen balance is a classical, integrative measure of whole-body protein metabolism, and its reversal under MK-677 dosing has shaped the rationale for investigating ghrelin receptor agonists in cachexia, sarcopenia, post-surgical recovery, and other catabolic research contexts. Subsequent work has explored related ghrelin pathway compounds (such as anamorelin) in cancer-related cachexia, but MK-677 remains the most-studied orally bioavailable representative of this class.

The crossover design also addressed inter-subject variability, strengthening the conclusion that the anabolic shift was specifically attributable to MK-677 administration rather than baseline metabolic heterogeneity. Together with the longer-duration aging and fracture trials, this work positions MK-677 as a mechanistically distinct research tool for studying integrated GH/IGF-1 axis activation under both physiological and stressed conditions.